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The role of the tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase (IDO1), in tumor escape and metastasis formation
was analyzed using two pairs of Ido1+a n dIdo1− murine breast cancer cell lines. Ido1 expression in 4T1 cells was knocked down
by shRNA, and Ido1 expression in NT-5 cells was upregulated by stable transfection. Growth of Ido1− tumors and spontaneous
metastasisformationwereinhibitedinimmunocompetentmice.AhigherlevelofcytotoxicTlymphocyteswasgeneratedbyspleen
cells from mice bearing Ido1− tumors than Ido1+ tumors. Tumor and metastatic growth was enhanced in immunodeﬁcient mice,
conﬁrming an intensiﬁed immune response in the absence of Ido1 expression. However, Ido1+ tumors grow faster than Ido1−
tumorsinimmunodeﬁcientSCID/beigemice(lackingT,B,andNKcells)suggestingthatsomeIdo1-controllednonimmunological
mechanisms may be involved in tumor cell growth regulation. In vitro experiments demonstrated that downregulation of Ido1 in
tumor cells was associated with decreased cell proliferation, increased apoptosis, and changed expression of cell cycle regulatory
genes, whereas upregulation of Ido1 in the cells had the opposite eﬀects. Taken together, our ﬁndings indicate that Ido1 expression
could exert immunological and nonimmunological eﬀects in murine breast tumor cells.
1.Introduction
Immune escape is one of the hallmarks of cancer [1]. There
are a variety of active mechanisms of immune suppression
that are elaborated by tumors to drive immune escape, such
as the loss of MHC class I molecules or tumor antigens,
inductionofTregulatorycells,andtheproductionofvarious
immunosuppressive molecules (IL-10, TGF-β, adenosine,
PGE2, etc.) [2–4]. One mechanism of immune escape that
has been linked to cancer is elevation of the tryptophan-
catabolizing enzyme, indoleamine 2,3-dioxygenase (IDO1)
[5–14].
IDO1canbeexpressedinmanytissueandcelltypes,such
as placenta, lung, gut, and epididymis [13, 15–17]. The
expression of IDO1 at the maternal-fetal interface in mice
placenta is believed to play a role in the protection of the
fetus from immunologic rejection by maternal immune
mechanisms [18]. Indeed, this has been supported experi-
mentally wherein the pharmacological inhibition of IDO1
by 1-methyltryptophan (1MT) resulted in the rejection of
allogeneic, but not syngeneic, murine fetuses [19–21]. Ido1
activation occurs commonly in tumor cells and/or tumor-
draining lymph nodes (TDLNs), and pharmacological inhi-
bitionofIDO1with1-MThasbeenshowntoresultinT-cell-
dependent antitumor responses in animal models [8, 22–
27]. 1-MT was observed to retard tumor outgrowth but was
unable to trigger complete tumor regression [6]. In vitro
studies indicate that IDO1 is capable of exerting suppressive
eﬀectsdirectlyonTcellsandcanactivatesuppressivepopula-
tions of regulatory T cells [8, 9]. Furthermore, soluble cyto-
toxic-T-lymphocyte-antigen-4- (CTLA4-) expressing T reg-
ulatorycellsinduceIDO1expressioninDC,convertingthem
into regulatory antigen-presenting cells (APCs) [24, 26].
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could induce IDO1 expression by DC [9, 13, 25]. A tumor-
related immune escape mechanism based on tryptophan
degradation by IDO1 has been proposed [22, 28]. Ido1 is
expressed by tumor cells; however, the level of Ido1 ex-
pression is signiﬁcantly lower than in placenta. Tumor cell
inhibition of immune response was only demonstrated for
Ido1-transfected clones, exhibiting 1000-fold increased ex-
pression of Ido1 mRNA relative to placental levels [22, 29].
Thus,aroleforIDO1intumorimmuneresponseisindicated
but requires further investigation.
In this study, we examined the impact of IDO1 on tumor
growth and metastasis in immune-competent and immune-
deﬁcient mice. Two murine breast cell lines, 4T1 and NT-
5, expressing Ido1 and missing Ido1 expression, respective-
ly, were utilized. NT-5 cells were transfected with an Ido1
expressionvectortoestablishanNT-5/Ido1+line.Expression
of Ido1 in 4T1 cells was knocked down by transfection with
an Ido1− speciﬁc shRNA expressing plasmid to establish a
4T1/Ido1− line. Using these two pairs of cell lines, we exam-
ined therelationship between Ido1 expression and cancercell
growth in vitro and in vivo. Our analysis of tumor growth
and metastasis, in immunocompetent and immunodeﬁcient
mice, revealed that IDO1 not only modulated the immuno-
logical system, but also played an important biological role
in tumor cell proliferation, cell cycle regulation, and anti-
apoptotic signaling.
2.MaterialsandMethods
2.1. Tumor Cell Lines. The NT-5 HER-2/neu-expressing tu-
mor cell line was provided by Elizabeth Jaﬀe, John Hopkins
University. The 4T1 mouse mammary tumor cell line was
purchased from American Type Culture Collection. Cells
were cultured in RPMI-1640 medium (Cellgro Mediatech,
Inc, Manassas, VA) supplemented with 10% FBS (Sigma-
Aldrich Co, St. Luis, MO).
2.2. Plasmid Construction and Cell Transfection. The mam-
malian expression vector for Ido1 was constructed by insert-
ing full-size mouse Ido1 cDNA into the vector pRc/CMV
(Invitrogen, Life Technologies Corp., Carlsbad, CA). NT-
5 cells were cloned, and IDO expression in the individual
cloneswasevaluated.TheclonewiththelowestIDO1expres-
sion was used for transfection with either Ido1 constructs or
control pRc/CMV vector using Lipofectamine 2000 accord-
ing to manufacturer instructions (Invitrogen). Stable trans-
fectants (NT-5/Ido1+ and NT-5/vector) were selected by
growth in a medium supplemented with 400μg/mL G418
(Sigma-Aldrich Co). IDO-positive 4T1 breast tumor cells
were also cloned, and the clone with highest IDO expres-
sion was transfected with shRNA against IDO containing
plasmid and the control plasmid (SABiosences). Stably
transfected 4T1/Ido1− and 4T1/vector cells were selected
with 600μg/mL of G418 (Sigma-Aldrich).
2.3. Real-Time PCR and Gene Expression Proﬁling. RNA
was isolated from the cells using the RNeasy kit from Qia-
gen (Valencia, CA), and the extracted RNA was converted
to cDNA using the RT
2 First Strand Kit from Super Array
BioscienceCorporation(Frederick,MD)accordingtomanu-
facturer’s protocols. Real-time PCR was carried out using
the Super Array RT
2 Real-Time SYBR Green PCR Master
Mix (Super Array Bioscience) and was performed on the ABI
Prism 7700 sequence detector real-time PCR system (AB Ap-
plied Biosystems, Foster City, CA). Primers for mouse Ido1
were forward 5 -GTACATCACCATGGCGTATG-3 ; reverse:
5 -CGAGGAAGAAGCCCTTGTC-3 . Standard curves were
generated from ﬁve 10-fold serial dilutions of tumor cell
cDNA, and no product could be observed in the negative
control lacking template. Diﬀerences in gene expression were
calculated by using the Ct method and normalized to
GAPDH according to the manual from Super Array Biosci-
ence (Super Array, Bioscience Corp., Frederick, MD).
The RT
2 Proﬁler PCR Array System and mouse cell cycle
regulation RT
2 Proﬁler PCR Array (Super Array, Bioscience
Corp) were used. Real-time PCR detection was carried out
per the manufacturer’s instructions. The experimental cock-
tail was prepared by mixing cDNA isolated from cell lines
with the RT
2 Real-Time SyBR Green/ROX qPCR Master Mix
(SABiosciences Corp., Frederick, MD). The mixtures were
equally aliquoted into the 96-well plate containing predis-
pensed gene-speciﬁc primer sets, then real-time PCR was
performed using the ABI Prism 7900HT (ABI, Applied Bio-
sytems Corp., Foster City, CA). Diﬀerences in genes expres-
sion were compared between 4T1/vector and 4T1/Ido1−
cells or between NT-5/vector and NT-5/Ido1+ cells. Analyses
of the raw data were done through the Super Array Data
Analysis Web Portal (Super Array Bioscience Corp.).
2.4. Enzymatic Assay for IDO Activity. IDO activity was
determined using what is described in [10, 30]. Brieﬂy, cell
extracts were prepared, mixed with an equal volume of
2x reaction buﬀer (100mM PBS, 40mM ascorbate, 20μM
methylene blue, 200μg/mL catalase, 800μM L-Tryptophan
(Aﬀymetrix, USB Inc, Cleveland, OH), pH 6.5), and incu-
bated at 37◦C for 30min in order to permit IDO-mediated
conversion of L-Trp into N-formylkynurenine. The reaction
was stopped with 30% trichloroacetic acid, and samples
were incubated at 50◦C for 30min to hydrolyze the N-
formylkynurenine produced to kynurenine. After centrifu-
gation, supernatants were collected and mixed with Ehrlich’s
reagent (0.8% p-dimethylaminobenzaldehyde in acetic acid)
in96-wellplates,andabsorbanceat490nmwasmeasuredon
a microplate reader. IDO activity is deﬁned as the amount of
enzyme required to produce 1nmol of kynurenine per hr per
mg of protein.
2.5. In Vitro Cell Proliferation Assay. The cells were cultured
in a 96-well plate for 2 days and pulsed with 0.2μCi/well
of 3H-thymidine overnight followed by collection of super-
natant. 50uL of supernatant was mixed with 2mL of Cyto-
Spin (MP, Biomedicals LLC, Solon, OH) and counted by
liquid scintillation counter (Wallac). The tumor cells were
also counted by Cellomics Array Scan HCS Reader (Thermo
Fisher, Pittsburgh, PA) following 3 days in culture as de-
scribed previously [31].Clinical and Developmental Immunology 3
2.6.FlowCytometryAnalysis. Cellswereculturedinacontrol
medium or in serum starvation conditions (RPMI with 0.1%
FBS or 0.3% FBS) for 3 days followed by culture in RPMI
with 10.0% FBS for 24 hours. Cells were stained with FITC-
conjugated antibromodeoxyuridine (BrdU) and/or propid-
ium iodide (PI) using FITC BrdU Flow Kit (BD Bioscien-
ces, Pharmingen, San Diego, CA) according to the manufac-
turer’s instruction. Flow cytometry was performed by CYAN
ADP (Beckman Counter, Brea, CA). The data were analyzed
with the Cytomation Summit v4.3 software.
2.7. In Vivo Local and Metastatic Tumors Assays. BALB/c,
FVB/N, and SCID-beige were purchased from The Jackson
Laboratory (Bar Harbor, ME) and used at 8-9 weeks of age.
Mice were housed in the University of Pittsburgh Cancer
Instituteanimalfacilitywhichisaccreditedforanimalcareby
theAmericanAssociationofLaboratoryAnimalCare.Exper-
iments were performed in accordance with the approved
institutional protocol and the guidelines of the Institutional
Animal Care and Use Committee. BALB/c and SCID-beige
mice were inoculated s.c. with 2.5 × 104 or 1.0 × 105 of
4T1/vector cells or 4T1/Ido1− cells per mouse; FBV/N and
SCID-beige mice were inoculated s.c. with 5 × 106 of NT-5
or NT-5/Ido1+ cells per mouse. Tumor growth was evaluated
by measurement of tumor diameters 3 times a week, and
the tumor volume was calculated as length × width2× 0.52.
All data is represented as mean ± SE. Experiments were
terminated when tumors reached 2.0cm in diameter. Each
group contained 10 mice. Experiments were repeated twice.
Lungs were harvested when tumors reached approximately
2cm in diameter and ﬁxed in Bounce solution. Metastases
were counted under a dissecting microscope.
2.8. Cytotoxicity Assay. Spleen cells from BALB/c mice bear-
ing 4T1/Ido1− or 4T1 tumors were cultured with irradiated
(15,000 rad) 4T1/Ido1− or 4T1 tumor cells for 5–8 days
in the presence of 300IU/mL of IL-2 in 24-well plates at
the ratio as 3 × 106 spleen cells: 1 × 106 tumor cells.
The cytotoxic activity of restimulated spleen cells was tested
against 51Cr-labeled 4T1/Ido1− or 4T1 cells at the eﬀector:
target ratio as 100:1. Spleen cells were distributed into V-96-
well plates preloaded with 51Cr-labeled tumor cells; 96-well
plates containing cell mixtures were centrifuged at 2000rpm
for 2 minutes and then incubated 4 hours at 37◦C. 25μLo f
supernatant was transferred into yttrium silicate scintillator-
coated microplates (LumaPlate-96, PerkinElmer) and left
overnight at RT. The level of β-emission released by 51Cr was
measured in a β-counter.
2.9.WesternBlotAnalysis. ThecellswerelysedinRIPAbuﬀer
supplemented with 1% CLAP cocktail (antipan, leupeptin,
pepstatin, and chymostatin) and 1mM PMSF. 50ug of pro-
tein extracts were resolved on 4.5–12% of SDS-PAGE and
transferred to PVDF membranes (Bio-Rad, Hercules, CA).
T h em e m b r a n e sw e r eb l o c k e dw i t h5 %n o n f a td r ym i l k
in TBST buﬀer, probed with antibodies against stratiﬁn
(1:200, Sigma), and Atm (1:200, Santa Cruz Biotechnology,
Inc, Santa Cruz, CA) for two hours at RT or overnight at
4◦C,andthenincubatedwithhorseradishperoxidase-labeled
secondary antibody (Santa Cruz). The signals were detected
by ECL (Amersham). Films were scanned and analyzed by
Image-QuanT data analysis software (Molecular Dynamics).
2.10. Statistical Analysis. Data are presented as mean ± SD.
Comparisons between values were performed using a two-
tailed Student’s t-test. For the comparison of multiple
groups, a one- or two-way ANOVA test was applied. For all
statistical analyses, the level of signiﬁcance was set at a pro
babilityof P<0.05.Allexperimentswererepeated2-3times.
3. Results
3.1. Establishment of Two-Paired Stable Clones (Ido1− and
Ido1+) of Murine Breast Cancer Cells. Initially, we measured
Ido1 expression in a panel of mouse tumor cell lines of dif-
fering histological origin. Two mouse breast tumor cell lines,
4T1 and NT-5, which showed diﬀerential expression of
Ido1, were chosen. 4T1 cells, derived from sporadic breast
tumor in BALB/c mice, are highly aggressive, metastatic, and
poorly immunogenic [32, 33]. NT-5 breast tumor cells are
derived from HER-2/neu-transgenic FBV/N mice, and they
are immunogenic [34].
We found that 4T1 cells express Ido1, whereas the level
of Ido1 gene expression in NT-5 cells was very low (Ido1−).
Clonal variation could be attributable whenever transfection
is performed on a polyclonal whole cell population. To avoid
this, our transfections were designed as follows: 4T1 breast
tumorcellswereclonedusingastandardapproachforselect-
ing single-cell clones. Ido1 expression, in these individual cell
clones, was evaluated. The clone the of the 4T1 tumor cells
with the highest Ido1 expression was transfected with Ido1
siRNA and a control vector to generate stable 4T1/Ido1− and
4T1/vector clones.
Similarly, NT-5 cells (expressing Ido1 at a very low level)
were also cloned, and the clone of NT-5 cells, with the lowest
level of Ido1 expression, was selected for transfection with
cDNA encoding Ido1 or control plasmid.
AsshowninFigure 1(a),verylowIdo1expressionwasde-
tectedbyRT-PCRin4T1/Ido1−cellscomparedwith4T1and
4T1/vector cells. The quantitative RT-PCR analysis revealed
78% downregulation of Ido1 in 4T1/Ido1− cells, and no
changes of Ido1 expression in 4T1/vector cells in comparison
with na¨ ıve 4T1 cells (Figure 1(a)).
IFN-γ is a known inducer of Ido1 [30]. We tested wheth-
er Ido1 expression could be induced by IFN-γ in 4T1, 4T1/
vector, and 4T1/Ido1− cells. Ido1 expression was strongly in-
creased (30-fold change) in 4T1, and 4T1/vector cells were
treated with IFN-γ (Figure 1(b)). However, Ido1 activa-
tion was abrogated in shRNA-transfected cells (4T1/Ido1−)
(Figure 1(b)).
We transfected an Ido1 vector and scramble vector into
the Ido1 low-expressing NT-5 cells and established stable
Ido1 expressing NT-5/Ido1+ and NT-5/vector clones. RT-
PCR analysis showed Ido1 expression in NT-5/Ido1+ cells,
and very low expression in NT-5/vector cells (Figure 1(c)
top);quantitativeRT-PCRdemonstrateda50.9-foldincrease4 Clinical and Developmental Immunology
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Figure 1: Generation of two pairs of Ido1+a n dIdo1− clones from murine breast cancer cells. (a) RT-PCR (top picture) real-time PCR
(bottom picture) analysis of Ido1 expression in 4T1 cells, cells transfected with vector (4T1/V), and cells transfected with shRNA for Ido1
(4T1/Ido1−). Fold change was compared with 4T1. (b) Real-time PCR analysis of the eﬀect of INF-γ treatment (INF-γ,2 5 n g / m L ,2 4
hours) on Ido1 expression in 4T1, 4T1/V, and 4T1/Ido1− cells. (c) Ido1 expression in NT-5 cells transfected with vector (NT-5/V) and
cells transfected with Ido1 cDNA (NT-5/Ido1+) detected by RT-PCR (top picture) and by Real-time PCR (bottom picture). (d) Enzymatic
IDO activity in 4T1, 4T1/Ido1−, NT-5, and NT-5/Ido1+ cells. IDO activity is deﬁned as the amount of enzyme required to produce 1nmol
of kynurenine per hr per 1mg of protein. All values are the means of four measurements.
of Ido1 expression in NT-5/Ido1+ cells in comparison to NT-
5/vector cells (Figure 1(c)).
Next, we tested enzymatic activity of IDO in 4T1, 4T1/
Ido1− NT-5, and NT-5/Ido1+ cells (Figure 1(d)). 4T1/Ido1−
cells demonstrated a signiﬁcant reduction of IDO activity in
comparison with 4T1 cells, while NT-5/Ido1+ cells showed
a signiﬁcant increase in IDO activity when compared with
NT-5 cells (Figure 1(d)).
3.2. Eﬀect of Ido1 Expression on Tumor Growth and Metas-
tasis Formation. To determine the role of IDO1 in tumor
growth, BALB/c mice were inoculated s.c. with 4T1/vector or
4T1/Ido1− tumor cells. 4T1/Ido1− tumors grew signiﬁcantly
(P<0.05) slower than 4T1/vector tumors (Figure 2(a)).
Mice bearing 2cm tumors were sacriﬁced according to our
IACUC-approved protocol, and surviving mice bearing tu-
mors of less than 2cm were counted at sequential timeClinical and Developmental Immunology 5
Table 1: Spontaneous lung metastases formation by 4T1/Ido1+, 4T1/Ido1− or NT-5/Ido1+, NT-5/Ido1− tumors in immunocompetent and
immunodeﬁcient mice.
Mice1 No. of spontaneous pulmonary metastases
4T1/Ido1+ tumors 4T1/Ido1− tumors
BALB/c 56; (41, 51, 56, 66, 182) 21; (6, 12, 21, 24, 29)∗
SCID-beige 54; (23, 24, 54, 75, 164) 69; (33, 54, 64, 69, 69, 71, 77, 92)
Mice1 NT-5/Ido1+t u m o r s N T - 5 / Ido1− tumors
FVB/N 6; (0, 2, 3, 5, 6, 7, 8, 11, 14) 1.5; (0, 0, 0, 0, 3, 4, 8, 10)∗
SCID-beige 25; (11, 12, 16, 24, 25, 26, 28, 32, 44)∗ 13; (0, 3, 12, 13, 13, 13, 14, 15)
1BALB/c and SCID-beige were inoculated s.c. with 2.5 × 104 4T1/Ido1+o r4 T 1 / Ido1− tumor cells. FVB/N and SCID-beige were inoculated s.c. with 5 × 106
NT-5/Ido1+o rN T - 5 / Ido1− tumor cells. When tumors reached about 2cm in diameter, lungs were harvested and ﬁxed in the Bounce solution. Metastases
were counted under dissecting microscope. ∗Signiﬁcantly (P<0.05) diﬀer from all other groups.
points in order to evaluate survival. At the time of complete
mortality in the control group, we observed nearly 50%
survival of mice bearing Ido1− tumors (Figure 2(b)).
The elevated survival of mice bearing 4T1/Ido1− tumors
m a yb ear e s u l to fal e s se ﬃcient immune response against
tumor cells demonstrating inhibited Ido1 expression. To
assess the immune response of BALB/c mice to 4T1/vector
and 4T1/Ido1− tumors, spleens of mice bearing tumors were
harvested,andspleencellsuspensionswereprepared.Freshly
prepared spleen cells had no cytotoxic activity against 4T1
tumor cells. Therefore, spleen cells were stimulated with
irradiated 4T1 tumor cells for 5–8 days in the presence
of IL-2 (300IU/mL). We observed no diﬀerence in the
abilities of irradiated 4T1/Ido1− and 4T1 (Ido1+) cells to
stimulate spleen cells and generate cytotoxic T cells. The
cytotoxic activity of stimulated spleen cells appeared after 5
days of stimulation and became more prominent after 7-8
days. Spleen cells obtained from irradiated 4T1/Ido1 tumor
cells from 4T1/Ido1− tumor bearing mice demonstrated a
higher cytotoxic activity than spleen cells from mice bear-
ing 4T1/vector tumors (Figure 2(c)). Furthermore, targeted
4T1/Ido1− tumor cells were more sensitive to the cytotoxic
activity of spleen cells than 4T1/vector cells (Figure 2(c)).
Spleen cells cultured in IL-2 (300IU/mL) without irradiated
tumor cells showed no cytotoxic activity (data no shown).
These results indicate that inhibition of 4T1/Ido1− tumor
growth in BALB/c mice could be due to an elevated immune
response against these cells as well as a greater sensitivity of
4T1/Ido1− cells to immune destruction.
To further test whether 4T1/Ido1− tumor growth inhi-
bition is immunologically mediated, immunocompetent
BALB/c mice or immunodeﬁcient SCID-beige mice (which
lack T, B, and NK cells) were inoculated s.c. with 4T1/vector
and 4T1/Ido1− cells. Our expectation was that if diﬀerences
in Ido1+ and Ido1− tumor growth are immune modulated,
then both tumors should grow similarly in SCID/beige mice.
Tumor growth from Ido1− cells was inhibited in comparison
with Ido1+ cells in BALB/c mice. As shown in Figure 2(d),
both Ido1− and Ido1+ tumors grew faster in immunodeﬁ-
cient SCID/beige mice than in immunocompetent BALB/c
mice. However, Ido1+ tumors grew faster than Ido1− tumors
in SCID/beige mice suggesting that some Ido1-controlled
nonimmunological mechanisms may be involved in tumor
cell growth regulation.
To test whether spontaneous pulmonary metastasis for-
mation is dependent on Ido1 gene expression, the number
of metastases in BALB/c and SCID/beige mice was counted
when tumors reached 2cm in diameter. We found that 4T1/
Ido1−cellsgeneratedsigniﬁcantlylessmetastasisinthelungs
of BALB/c mice than 4T1 cells (92 versus 396) (Table 1). The
pulmonary metastases observed in immunodeﬁcient SCID-
beige mice bearing Ido1− tumors were higher than in the
immunocompetent BALB/c mice bearing Ido1− tumors
(Table 1).
To further elucidate the role of IDO1, in tumor growth
andmetastasisformation,weusedNT-5/Ido1−cellsandNT-
5/Ido1+ tumor cells and FVB/N mice that are immunocom-
petent for NT-5 cells. It is known that NT-5 breast tumor
cells, derived from HER-2/neu-transgenic FBV/N mice, are
immunogenic [34]. Indeed, tumor growth was prevented
when1 ×106 NT-5cellswereinoculatedintomice.However,
inoculation of 5 × 106 NT-5 cells resulted in tumor develop-
ment. Tumor growth in many FVB/N mice was associated
with enormous necrosis which made it diﬃcult to measure
tumorsize;therefore,miceweresacriﬁcedwhentheyshowed
signs of moribund, and lung metastases were counted. We
found that NT-5/Ido1+ cells are more metastatic than NT-
5/Ido−cells in immunocompetent FVB/N mice (Table 1).
The numbers of metastases developed from NT-5/Ido1+
cells and NT-5/Ido− cells in immunodeﬁcient SCID/beige
mice were signiﬁcantly higher than in FVB/mice (Table 1).
However, even in immunodeﬁcient mice, NT-5/Ido1− cells
developed less metastasis than NT-5/Ido1+ cells.
Taken together, these results indicate that Ido1 plays role
in tumor growth and metastasis formation.
3.3. Eﬀect of Ido1 Expression on Apoptosis Changes Cell Cycle
and Tumor Cell Proliferation In Vitro. The diﬀerences in
Ido1+a n dIdo1− tumor growth in immunodeﬁcient mice
indicate a possible role of Ido1 in apoptosis and tumor cell
proliferation. To analyze cell cycle distribution, in Ido1+a n d
Ido1− cells, we used ﬂow cytometry and FITC-conjugated
antibromodeoxyuridine (BrdU) and/or propidium iodide
(PI) staining. The approach relies on the detection of 5 -
bromo-2 -deoxyuridine (BrdU) incorporation which iden-
tiﬁes DNA-replicating cells, and PI staining reveals the dis-
tribution of cells in three major phases of the cycle (G1 ver-6 Clinical and Developmental Immunology
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Figure 2: Eﬀect of Ido1 expression on tumor growth and spontaneous metastasis formation. (a) BALB/c mice were inoculated s.c. with
1 × 105cells/mouse of 4T1/vector or 4T1/Ido1− tumor cells, and tumor growth was monitored. (b) Percentage of surviving mice bearing
4T1/vector and 4T1/Ido1− tumors. (c) Cytotoxic activity of spleen cells from mice bearing 4T1 or 4T1/Ido1− tumors against 4T1 and
4T1/Ido1− tumor cells. Spleen cells from mice bearing 4T1/vector or 4T1/Ido1− tumors were cultured with irradiated 4T1/vector tumor
cells and 300IU/mL of IL-2 for 5–8 days. The cytotoxic activity of the spleen cells was tested against 51Cr-labeled 4T1 or 4T1/Ido1− cells at
the E:T ratio 100:1. (d) Growth of 4T1 and 4T1/Ido1− tumors in immunocompetent BALB/c and immunodeﬁcient SCID-beige mice.
sus S versus G2/M) and makes it possible to detect apoptotic
cells with fractional DNA content.
Figure 3 represents the results of the experiments in
which double staining was applied. Bivariate distribution
(contour map) of DNA content and BrdU incorporation in
4T1 and 4T1/Ido1− cells are shown. The 4T1/Ido1− cells
growing in control media have signiﬁcantly (P<0.05)
higher percentage of apoptotic cells than 4T1/Ido1+ cells.
Starvationisaconditionthatoftenoccurswithinthetumors.
We analyzed the eﬀect of starvation conditions (low serum
in culture medium) on apoptosis induction in 4T1/Ido1+
and 4T1/Ido1− cells. Here, the proportion of apoptotic 4T1/
Ido1− cells reached 86%, which is approximately 3 times
higher than that observed in the 4T1/Ido1+ cell population.
The 4T1/Ido1+ cells recover faster after starvation (Figure 3).
Cell cycle phase distribution was also diﬀerent in 4T1/Ido1+
and 4T1/Ido1− cell populations in control media and under
starvation (Figure 3). Control cells showed a signiﬁcantly
higher proportion of cells in the S phase than 4T1/Ido1−
cells. 4T1/Ido1+ growing in low serum demonstrated a high-
er proportion of cells in M and G0 phases than 4T1/Ido1−
cells. We then compared the proliferation of 4T1/Ido1+a n d
4T1/Ido1− c e l l sa sw e l la sN T - 5 / Ido1− and NT-5/Ido1+c e l l s
in vitro. The results of 3H-thymidine incorporation showed
a signiﬁcant reduction in proliferation of Ido1− cells in
comparison to Ido1+ cells (Figure 4(a)). Next, the same pairs
of Ido1+/Ido1− cells were grown for 3 days and counted
as described previously [31]. As shown in Figure 4(b),Clinical and Developmental Immunology 7
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Figure 3: Flow cytometry analysis of apoptosis and cell cycle in Ido1+ and Ido1− cells. 4T1 and 4T1/Ido1− cells were cultured in normal
medium(10%FBS),orunderstarvationcondition(0.3%FBS)for3daysfollowedbya24hourrecoveryinnormalmedium.Flowcytometry
analyses of cells stained with FITC-conjugated antibromodeoxyuridine (BrdU) and propidium iodide (PI) were performed. The data are
presented as a percentage of cells in apoptosis (A), G0, S, and M phases.
the inhibition of Ido1 activity in 4T1 cells was associated
with an inhibition in 4T1/Ido1− cell proliferation, whereas
overexpression of Ido1 in NT5/Ido1+ cells stimulated tumor
cell proliferation.
3.4. Ido1 and Cell Cycle Gene Expression. To further analyze
the diﬀerences of the cell cycle regulation in Ido1+ and
Ido1− cells, the cell cycle genes expressions were investigated
(Table 2). We used the Mouse Cell Cycle PCR Array from
SABiosciences to compare cell cycle gene expression in two
pairs of positive and negative Ido1 tumor cells.
Ido1 inhibition in 4T1 tumor cells was associated with
signiﬁcant changes in the expression of 40 cell cycle genes
involved in the G1/S transition, S phase, G2/M transition,
checkpoints, and M phase, and the majority of the altered
genes were downregulated. Ido1 expression in NT-5/Ido1+8 Clinical and Developmental Immunology
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Figure 4: In vitro proliferation and western blot analysis ATM and SFN proteins in Ido1+ and Ido1− breast tumor cells. (a) Analysis of 3H
thymidine incorporation and (b) cell counting using Cellomics Array Scan in 4T1/vector, 4T1/Ido1−, NT-5/vector, and NT-5/Ido1+ cells.
(c) Western blots analysis of ATM and (d) SFN (14-3-3 sigma protein) expression in 4T1/vector, 4T1/Ido1−, NT-5/vector, and NT-5/Ido1+
cells.
cells correlated with changes in the expression of 14 genes,
13 of which were upregulated (Table 2). The expression of
four genes (Trp63(p63), dystonin (Dst), stromal antigen1
(Stag1) and microtubule-actin crosslinking factor (Macf1))
was lower in Ido1 downregulated cells, and higher with Ido1
upregulation(Table 2).Toverifywhetherthechangesingene
expression are associated with upregulation of IDO1 protein
expression in Ido1+ and Ido1− cells, we performed a western
blot analysis of the cell cycle regulators ATM and stratiﬁn
(Sfn) [35, 36].
Atm (ataxia telangiectasia mutated) is an important cell
cycle regulation gene encoding a serine/threonine protein
kinase that is recruited and activated by DNA double-
strand breaks. ATM phosphorylates several key proteins that
initiate activation of the DNA damage checkpoint, leading
to cell cycle arrest, DNA repair, or apoptosis [35, 36].
Atm expression was signiﬁcantly decreased (−18.3-fold) in
4T1/Ido1− cells and only slightly changed (1.7-fold) in NT-
5/Ido1+( Table 2). As demonstrated in Figure 4(c),A T Mi s
expressed in 4T1/vector (Ido1+) cells, and ATM production
is dramatically reduced in Ido1− cells.
Stratiﬁn (Sfn), also named 14-3-3 sigma, is a multifunc-
t i o n a lp r o t e i ni n v o l v e di nc e l lc y c l er e g u l a t i o n[ 36]. Down-
regulationofIdo1 in4T1cellsisassociatedwithupregulation
of Sfn gene expression (12 fold); and upregulation of Ido1 in
NT5 cells is associated with a decreased level (−7f o l d )o fS f n
gene expression (Table 2).
Western blot analysis demonstrated that SFN protein is
increased in Ido1− cells, and it is reduced in Ido1+ cells
(Figure 4(d)). Thus, the results of the PCR analysis of Atm
and Sfn gene expression are consistent with the results of the
western blot analysis of the ATM and SFN proteins
4. Discussion
We ﬁrst analyzed the impact of Ido1 expression on tumor
growth and spontaneous pulmonary metastasis formation
and then investigated the IDO1-regulated mechanisms in-
volved in tumorigenesis. One of the key experimental stra-
tegies to elucidate the function of a gene in vitro and
in vivo is the speciﬁc inhibition or upregulation of its
expression. Here, we explored both approaches. Ido1+ cells
were transected with plasmid expressing shRNA for Ido1,
and Ido1− c e l l sw e r et r a n s f e c t e dw i t hIdo1 cDNA. These two
pairsofIdo+ andIdo−cloneswereevaluatedthroughoutour
investigation.
We found that 4T1/Ido1+ tumors grew faster than
4T1/Ido1− tumors in immunocompetent mice. GrowthClinical and Developmental Immunology 9
Table 2: Ido1 and the cell cycle genes expression in mouse breast tumor cells.
Fold changes in cell cycle genes expression
4T1/Ido1+v e r s u s4 T 1 / Ido1− NT-5/Ido1− versus NT-5/Ido1+
G1 phase and G1/S transition
1 CAMK2a 1.3 5.4
2 GPR132 4.8 1.8s
3I T G B 1 −17.6 1.8
4 PPP2r3a 5.1 2.9
5 PPP3ca −4.2 2.1
6S K P 2 −3.8 1.5
S phase and DNA replication
7D N A J C 2 7 . 7 1 . 5
8 MKI67 8.8 2.3
9 MRE11a −4.9 1.2
10 MSH2 −3.3 1.5
11 PCNA −5.4 1.1
12 RAD17 −6.1 1.8
13 RAD51 −5.2 1.3
Mp h a s e
14 BRCA2 −7.1 1.8
15 CCNA1 19.1 4.4
16 CCNB1 −10.9 −6.8
17 CDC25a −3.1 1.9
18 NEK2 −4.4 1.1
19 NPM2 −1.7 3.1
20 PRM1 10.0 1.6
21 RAD21 3.3 2.8
22 SMC1a 8.6 1.4
23 STAG1 −5.8 3.0
G2 phase and G2/M transition
24 CHEK1 −31.2 1.3
25 DNAJC2 −7.7 1.5
Cell cycle checkpoint; cell cycle arrest
26 BRCA2 −7.1 1.8
27 CDK5rap1 −6.5 1.2
28 CDKN1a(p21) 11.6 2.0
29 CDKN1b(p27) −6.8 1.0
30 CDKN2a(p16) 9.9 2.4
31 CASP3 −5.6 1.4
32 CHEK1 −31.2 1.3
33 DDIT3 −1.8 14.3
34 DST −11.2 7.3
35 HUS1 −7.7 1.0
36 INHA 10.0 5.0
37 MACF1 −8.7 3.1
38 NOTCH2 −1.8 3.1
39 PKD1 −2.0 3.5
40 PMP22 −1.9 6.110 Clinical and Developmental Immunology
Table 2: Continued.
Fold changes in cell cycle genes expression
4T1/Ido1+v e r s u s4 T 1 / Ido1− NT-5/Ido1− versus NT-5/Ido1+
41 SFN 12.0 −7.0
Regulation of the cell cycle
42 ABL1 −3.4 1.3
43 ATM −18.3 1.7
44 BRCA1 −12.5 1.3
45 CCNC −11.0 1.0
46 PBL1 −8.9 1.5
47 E2F3 3.3 −1.2
48 TRP63(p63) −27.3 6.8
4T1: stable clone with shRNA-negative control vector pGeneClip/Neomycin; 4T1/Ido1−: stable clone with shRNA for IDO.
NT-5: stable clone with control vector pRc/CMV/Neomycin; NT-5/Ido1+: stable clone with cDNA IDO.
∗A positive value (normal font) indicates fold of gene upregulation; a negative value (bold) indicates fold of gene downregulation. Genes which were found
up/downregulated more than 3-fold at least in the one of the cell line are presented.
inhibition of Ido1− tumor cells can be attributed to a more
eﬃcient immune response. This conclusion is based on the
following. (1) Spleen cells from mice bearing 4T1/Ido1−
tumors generated a higher level of cytotoxic T cells (CTCs).
T h e s eC T C sw e r ea b l et od e s t r o y4 T 1 / Ido1− cells and 4T1/
Ido1+ cells. However, their cytotoxic eﬀects were higher
against4T1/Ido1−cells,mostlikelyduetoahighersensitivity
of these cells to apoptotic signaling. (2) In the absence
of major immune mechanisms in SCID/beige mice, the
growth of Ido1− tumors was accelerated, suggesting a
role for the immune system in Ido1-dependent control of
tumor growth. These ﬁndings are consistent with previous
publications, demonstrating the role of IDO1 in tumor
immunosuppression [5–9, 12–14, 37].
Activation of Ido1 by IFN-γ links inﬂammation and
cancer immune surveillance [11, 28, 35], and an increase
in IFN-γ within the tumor microenvironment also induced
IDO1expressioninAPCsandDCsthatlocalizetothetumor-
draining lymph nodes [38]. We found that IFN-γ treatment
induced Ido1 expression in Ido1+ cells and had no eﬀect
on Ido1− cells. Recently, a mouse genetic study revealed
a critical role for IDO1 in supporting inﬂammatory skin
carcinogenesis [26]. An analysis of IDO1 dysregulation in
cancer showed that JAK/STAT and NF-κB signaling are also
essential for IDO1 induction in oncogenically transformed
skin epithelial cells [39]. The anti-inﬂammatory agent, ethyl
pyruvate, was found to be able to block Ido1 expression,
indicating a link between IDO1 and inﬂammatory processes
[39].
For the ﬁrst time, we showed that Ido1 regulates tu-
mor metastasis via immunosuppressive mechanisms. Ido1+
tumors develop dramatically higher levels of spontaneous
pulmonary metastasis in immunocompetent mice than
Ido1− tumors. Levels of lung metastasis in SCID/beige
mice (deﬁcient in T cells, B cells, and NK cells) are high-
er than in immunocompetent mice, thus conﬁrming an
immunosuppressiveroleforIDO1inspontaneousmetastasis
formation.
In contrast to our expectation, growth of the Ido1−
tumors was slower than growth of Ido1+ tumors in immun-
odeﬁcient SCID/beige mice, suggesting that some Ido1-
associated nonimmunological mechanisms may be involved
in tumor cell growth regulation. It is conceivable that Ido1−
cells may have an increased sensitivity to apoptosis signaling
or slower cell cycle progression and proliferation than Ido1+
cells.Ourinvitrostudyrevealedmultiplediﬀerencesbetween
Ido1− and Ido1+ cell populations suggesting the complexity
of IDO1- regulated tumor cell functions. Ido1− cells grow
slower than Ido1+ cells. Similarly, the inhibition of IDO
expression in rat NMU-induced breast cancer showed the
reduced cell proliferation in vitro [40].
Ido1+ cells have small proportions of apoptotic cells in
normal media and in starved conditions, and they recover
better after starvation. In contrast, 4T1/Ido1− cells, in which
the Ido1 gene was down-regulated via shRNA transfection,
have dramatically increased sensitivity to apoptosis, thus
suggesting an important antiapoptotic function of Ido1 in
tumor cells. However, molecular pathways involved in Ido1-
associated apoptosis signaling remain virtually unexplored,
oﬀering new areas for investigation.
Cell cycle distributions within Ido1− and Ido1+ tumor
cell populations also diﬀer in that Ido1+ cells show a higher
proportion of cells in S and M phases than Ido1− cells.
Using a comparative RT-PCR analysis of cell cycle regulatory
gene expression, we found that downregulation of Ido1
is associated with decreased expression of multiple genes
involved in regulation of G1/S transition, S phase, G2/M
transition, checkpoints, and M phase, whereas upregulation
of Ido1 induces expression of these genes. Protein analysis
of the products of two genes, stratiﬁn (SFN)a n dATM,i n
Ido1+a n dIdo1− cells show that the up- and downregula-
tion of these genes correlates with the increased/decreased
production of their respective proteins. Thus, the roles of
Ido1 in breast tumor growth are complex and suggest the
involvement of additional nonimmunological mechanisms.
5. Conclusion
Our primary ﬁnding is that Ido1 expression has immuno-
logical and nonimmunological eﬀects on breast tumorClinical and Developmental Immunology 11
growth and spontaneous pulmonary metastasis formation.
We demonstrated that IDO1 is involved in the regulation of
tumor cell proliferation in vitro and in vivo. Ido1 expression
also aﬀects apoptosis in tumor cells. The involvement of
IDO1 in cell cycle regulation and tumor cell stress response,
in addition to the known role of IDO1 in tumor immuno-
suppression, make it an attractive target for antitumor
therapy.
Authors’ Contribution
V. Levina and Y. Su have equally contributed to this work.
Acknowledgments
The authors thank Dr. Xiaojun Huang for technical support,
and Dr. Brian Nolen for paper editing. This work was sup-
ported by the DOD, Award BC051720, Hillman Foundation
(E. Gorelik), NIH Grants DK68575, and Award N2929/2907,
the Magee Women’s Research Institute and Foundation. This
workperformedusingtheUPCIFlowCytometryFacilitywas
supported in part by Award P30CA047904.
References
[1] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the
next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[2] R.Kim,M.Emi,andK.Tanabe,“Cancerimmunoeditingfrom
immune surveillance to immune escape,” Immunology, vol.
121, no. 1, pp. 1–14, 2007.
[3] T. Raskovalova, A. Lokshin, X. Huang et al., “Inhibition of
cytokine production and cytotoxic activity of human antime-
lanoma speciﬁc CD8+ and CD4+ T lymphocytes by adeno-
sine-protein kinase A type I signaling,” Cancer Research, vol.
67, no. 12, pp. 5949–5956, 2007.
[4] Y. Su, E. K. Jackson, and E. Gorelik, “Receptor desensitization
andblockadeofthesuppressiveeﬀectsofprostaglandinE2and
adenosine on the cytotoxic activity of human melanoma-in-
ﬁltrating T lymphocytes,” Cancer Immunology, Immunother-
apy, vol. 60, no. 1, pp. 111–122, 2011.
[5] A. J. Muller, J. B. DuHadaway, P. S. Donover, E. Sutanto-
Ward, and G. C. Prendergast, “Inhibition of indoleamine 2,3-
dioxygenase, an immunoregulatory target of the cancer sup-
pression gene Bin1, potentiates cancer chemotherapy,” Nat-
ure Medicine, vol. 11, no. 3, pp. 312–319, 2005.
[ 6 ]A .J .M u l l e r ,W .P .M a l a c h o w s k i ,a n dG .C .P r e n d e r g a s t ,
“Indoleamine 2,3-dioxygenase in cancer: targeting patholog-
ical immune tolerance with small-molecule inhibitors,” Expert
Opinion on Therapeutic Targets, vol. 9, no. 4, pp. 831–849,
2005.
[7] D. H. Munn, “Indoleamine 2,3-dioxygenase, tumor-induced
tolerance and counter-regulation,” Current Opinion in Immu-
nology, vol. 18, no. 2, pp. 220–225, 2006.
[8] D. H. Munn and A. L. Mellor, “Indoleamine 2,3-dioxygenase
and tumor-induced tolerance,” Journal of Clinical Investiga-
tion, vol. 117, no. 5, pp. 1147–1154, 2007.
[ 9 ] D .H .M u n na n dA .L .M e l l o r ,“ IDO and tolerance to tumors,”
Trends in Molecular Medicine, vol. 10, no. 1, pp. 15–18, 2004.
[10] Y. Kudo and C. A. R. Boyd, “Human placental indoleamine
2,3-dioxygenase: cellular localization and characterization of
anenzymepreventingfetalrejection,”BiochimicaetBiophysica
Acta, vol. 1500, no. 1, pp. 119–124, 2000.
[11] A. L. Mellor and D. H. Munn, “Tryptophan catabolism and T-
cell tolerance: immunosuppression by starvation?” Immunol-
ogy Today, vol. 20, no. 10, pp. 469–473, 1999.
[12] D. H. Munn, E. Shaﬁzadeh, J. T. Attwood, I. Bondarev, A.
Pashine, and A.L. Mellor, “Inhibition of T cell proliferation by
macrophage tryptophan catabolism,” Journal of Experimental
Medicine, vol. 189, no. 9, pp. 1363–1372, 1999.
[13] G. C. Prendergast, “Immune escape as a fundamental trait of
cancer: focus on IDO,” Oncogene, vol. 27, no. 28, pp. 3889–
3900, 2008.
[14] G. C. Prendergast, R. Metz, and A. J. Muller, “IDO recruits
Tregs in melanoma,” Cell Cycle, vol. 8, no. 12, pp. 1818–1819,
2009.
[15] R. Yoshida and O. Hayaishi, “Induction of pulmonary indo-
leamine 2,3-dioxygenase by intraperitoneal injection of bacte-
rial lipopolysaccharide,” Proceedings of the National Academy
of Sciences of the United States of America,v o l .7 5 ,n o .8 ,p p .
3998–4000, 1978.
[16] R. Yoshida, J. Imanishi, and T. Oku, “Induction of pulmonary
indoleamine 2,3-dioxygenase by interferon,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 78, no. 1, pp. 129–132, 1981.
[17] S. Lob, A. K¨ onigsrainer, H. G. Rammensee, G. Opelz, and P.
Terness, “Inhibitors of indoleamine-2,3-dioxygenase for can-
certherapy:canweseethewoodforthetrees?”Nature Reviews
Cancer, vol. 9, no. 6, pp. 445–452, 2009.
[18] D.H.Munn,M.Zhou,J.T.Attwoodetal.,“Preventionofallo-
geneic fetal rejection by tryptophan catabolism,” Science, vol.
281, no. 5380, pp. 1191–1193, 1998.
[19] L. Huang, B. Baban, B. A. Johnson, and A. L. Mellor, “Den-
dritic cells, indoleamine 2,3 dioxygenase and acquired im-
mune privilege,” International Reviews of Immunology, vol. 29,
no. 2, pp. 133–155, 2010.
[20] P. Ligam, U. Manuelpillai, E. M. Wallace, and D. Walker,
“Localisation of indoleamine 2,3-dioxygenase and kynurenine
hydroxylase in the human placenta and decidua: implications
for role of the kynurenine pathway in pregnancy,” Placenta,
vol. 26, no. 6, pp. 498–504, 2005.
[21] N. Miwa, S. Hayakawa, S. Miyazaki et al., “IDO expres-
sion on decidual and peripheral blood dendritic cells and
monocytes/macrophages after treatment with CTLA-4 or in-
terferon-γ increase in normal pregnancy but decrease in spon-
taneous abortion,” Molecular Human Reproduction, vol. 11,
no. 12, pp. 865–870, 2006.
[22] C. Uyttenhove, L. Pilotte, I. Th´ eate et al., “Evidence for a
tumoral immune resistance mechanism based on tryptophan
degradation by indoleamine 2,3-dioxygenase,” Nature Medi-
cine, vol. 9, no. 10, pp. 1269–1274, 2003.
[23] M. Friberg, R. Jennings, M. Alsarraj et al., “Indoleamine 2,3-
dioxygenase contributes to tumor cell evasion of T cell-med-
iated rejection,” International Journal of Cancer, vol. 101, no.
2, pp. 151–155, 2002.
[24] M. D. Sharma, B. Baban, P. Chandler et al., “Plasmacy-
toid dendritic cells from mouse tumor-draining lymph nodes
directly activate mature Tregs via indoleamine 2,3-dioxygen-
ase,” Journal of Clinical Investigation, vol. 117, no. 9, pp. 2570–
2582, 2007.
[25] A. J. Muller and G. C. Prendergast, “Indoleamine 2,3-dioxy-
genase in immune suppression and cancer,” Current Cancer
Drug Targets, vol. 7, no. 1, pp. 31–40, 2007.
[26] A. J. Muller, M. D. Sharma, P. R. Chandler et al., “Chronic
inﬂammation that facilitates tumor progression creates local12 Clinical and Developmental Immunology
immune suppression by inducing indoleamine 2,3 dioxyge-
nase,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 105, no. 44, pp. 17073–17078,
2008.
[27] J. Godin-Ethier, L. A. Hanaﬁ, C. A. Piccirillo, and R. Lapointe,
“Indoleamine 2,3-dioxygenase expression in human cancers:
clinical and immunologic perspectives,” Clinical Cancer Re-
search, vol. 17, no. 22, pp. 6985–6991, 2011.
[28] D. H. Munn, A. L. Mellor, M. Rossi, and J. W. Young,
“Dendritic cells have the option to express IDO-mediated
suppression or not [4],” Blood, vol. 105, no. 6, p. 2618, 2005.
[29] N. Yoshida, K. Ino, Y. Ishida et al., “Overexpression of
indoleamine 2,3-dioxygenase in human endometrial carci-
noma cells induces rapidtumor growth in a mouse xenograft
model,” Clinical Cancer Research, vol. 14, no. 22, pp. 7251–
7259, 2008.
[30] O. Takikawa, T. Kuroiwa, F. Yamazaki, and R. Kido, “Mecha-
nism of interferon-γ action. Characterization of indoleamine
2,3-dioxygenase in cultured human cells induced by inter-
feron -γ and evaluation of the enzyme-mediated tryptophan
degradation in its anticellular activity,” Journal of Biological
Chemistry, vol. 263, no. 4, pp. 2041–2048, 1988.
[31] V. Levina, Y. Su, B. Nolen et al., “Chemotherapeutic drugs and
human tumor cells cytokine network,” InternationalJournalof
Cancer, vol. 123, no. 9, pp. 2031–2040, 2008.
[32] C. J. Aslakson and F. R. Miller, “Selective events in the
metastatic process deﬁned by analysis of the sequential dis-
semination of subpopulations of a mouse mammary tumor,”
Cancer Research, vol. 52, no. 6, pp. 1399–1405, 1992.
[33] B. A. Pulaski and S. Ostrand-Rosenberg, “Unit 20.2 mouse
4T1 breast tumor model,” in Current Protocols in Immunology,
chapter 20, John Wiley & Sons, New York, NY, USA, 2001.
[34] R.T.Reilly,M.B.C.Gottlieb,A.M.Ercolinietal.,“HER-2/neu
is a tumor rejection target in tolerized HER-2/neu transgenic
mice,” Cancer Research, vol. 60, no. 13, pp. 3569–3576, 2000.
[35] M. B. Kastan and D. S. Lim, “The many substrates and func-
tions of ATM,” Nature Reviews Molecular Cell Biology, vol. 1,
no. 3, pp. 179–186, 2000.
[36] C.Laronga,H.Y.Yang,C.Neal,andM.H.Lee,“Associationof
the cyclin-dependent kinases and 14-3-3 sigma negatively reg-
ulates cell cycle progression,” Journal of Biological Chemistry,
vol. 275, no. 30, pp. 23106–23112, 2000.
[37] X. Zheng, J. Koropatnick, M. Li et al., “Reinstalling antitu-
mor immunity by inhibiting tumor-derived immunosuppres-
sive molecule IDO through RNA interference,” Journal of Im-
munology, vol. 177, no. 8, pp. 5639–5646, 2006.
[38] G. C. Prendergast, R. Metz, and A. J. Muller, “Towards a
genetic deﬁnition of cancer-associated inﬂammation: role of
the IDO pathway,” American Journal of Pathology, vol. 176, no.
5, pp. 2082–2087, 2010.
[39] A. J. Muller, J. B. Duhadaway, D. Jaller, P. Curtis, R. Metz,
a n dG .C .P r e n d e r g a s t ,“ I m m u n o t h e r a p e u t i cs u p p r e s s i o no f
indoleamine2,3-dioxygenaseandtumorgrowthwithethylpy-
ruvate,” Cancer Research, vol. 70, no. 5, pp. 1845–1853, 2010.
[ 4 0 ]M .H i l l ,V .P e r e i r a ,C .C h a u v e a ue ta l . ,“ H e m eo x y g e n a s e - 1
inhibitsratandhumanbreastcancercellproliferation:mutual
cross inhibition with indoleamine 2,3-dioxygenase,” FASEB
Journal, vol. 19, no. 14, pp. 1957–1968, 2005.